VISTA Eye Specialist Revolutionizes Dry Eye Treatment with Groundbreaking Research and Advanced Technology

December 27, 2024 11:00 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

PETALING JAYA, Malaysia, Dec. 27, 2024 /PRNewswire/ -- VISTA Eye Specialist (VISTA), Malaysia's leading eye care provider, proudly announces a major milestone in the treatment of dry eye disease. A groundbreaking study led by Dr. Aloysius Joseph Low, Medical Director and Ms. Azarina Abdullah, Optometrist has been published in the esteemed Journal of Health Science and Medical Research. This achievement firmly establishes VISTA as a trailblazer in ophthalmology innovation across Southeast Asia.

An Optometrist from VISTA Eye Specialist is performing the IRPL therapy for dry eye patient.
An Optometrist from VISTA Eye Specialist is performing the IRPL therapy for dry eye patient.

Dry eye disease is on the rise worldwide, driven by modern lifestyle factors such as prolonged screen time, air-conditioned environments, and aging populations among others. This chronic condition affects millions, causing significant discomfort and diminishing quality of life for sufferers.

Innovative E>Eye IRPL Therapy

In response to the growing burden of dry eye disease, VISTA is spearheading a revolutionary approach with E>Eye Intense Regulated Pulsed Light (IRPL) therapy, a cutting-edge treatment designed to address evaporative dry eye disease caused by meibomian gland dysfunction (MGD).

The study, titled "The Effectiveness of E>Eye Intense Regulated Pulsed Light Therapy in Treating Evaporative Dry Eye Disease among Southeast Asian Patients," demonstrates the exceptional efficacy of this advanced therapy in restoring gland function, stabilizing tears, and improving overall eye comfort for patients in the region.

Key Findings of the Research:

  • Effective with Minimal Treatment: As few as three consecutive sessions of E>Eye IRPL therapy delivered measurable improvements in meibomian gland function and tear stability, providing long-term relief for patients.
  • Tailored for Southeast Asian Needs: The therapy effectively addresses lifestyle and environmental factors specific to the region.
  • Lasting Comfort and Relief: Patients reported significant improvements in their quality of life following treatment.

"Our mission has always been to transform lives through safe, effective, and innovative eye care solutions," said Dr Aloysius Joseph Low. "Dry eye disease not only causes physical discomfort but also disrupts the ability to fully engage in activities that bring joy and purpose. With E>Eye IRPL therapy, we empower our patients to restore their vision and reclaim their life's Ikigai – their reason for being."

Fostering Ikigai Through Vision Health

In Japanese culture, Ikigai refers to the intersection of what you love, what you are good at, what the world needs, and what you can be rewarded for – essentially, living a life of purpose. Vision plays a pivotal role in fulfilling one's Ikigai, from pursuing meaningful work to enjoying time with loved ones and engaging in personal passions.

VISTA's innovative treatments, like E>Eye IRPL therapy, are designed not just to treat eye conditions but to enable patients to live fuller, more purposeful lives. Whether it's regaining confidence in professional pursuits or reconnecting with hobbies and relationships, VISTA's approach to eye care is deeply aligned with the holistic well-being of its patients.

A Collaborative Innovation

The achievement reflects a strong partnership between VISTA and ESW Vision, the global developer of the E>Eye IRPL system and DED diagnostic unit Tearcheck®. Highlighting this collaboration, Ing. Peter BARANOVIC, MBA - Commercial Director at ESW Vision said:

"We are delighted to collaborate with VISTA Eye Specialist in bringing our Dry Eye Patients Management portfolio of products, such as the diagnostic unit Tearcheck® and E>Eye as IRPL therapy to Southeast Asia. This partnership underscores our shared commitment to advancing dry eye treatment and enhancing patient satisfaction and great outcomes in the region. We as well highly appreciated the participation in our global data collection that helps us improve our services and products even more."

Leading the Future of Eye Care

VISTA's dedication to delivering evidence-based, patient-centered solutions continues to redefine standards in ophthalmology. This latest breakthrough solidifies VISTA's position as a leader in the field, in line with its mission: "Safely help people see their best. Changing lives."

Through innovative treatments like E>Eye IRPL therapy, VISTA remains steadfast in transforming lives and setting new benchmarks in the delivery of exceptional eye care across Southeast Asia.

About VISTA Eye Specialist

Founded on a commitment to clinical excellence and patient-focused care, VISTA Eye Specialist is Malaysia's premier provider of comprehensive eye health services with 18 centres across the nation. From advanced cataract surgery and LASIK to cutting-edge dry eye treatments, VISTA offers the most innovative solutions to ensure optimal vision and well-being for its patients.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.